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Previewsinhibitors CP-690,550 and Pyridone6
were found to inhibit STAT3 less effi-
ciently than STAT1, STAT, and STAT6
(Yoshida et al., 2012). Thus, at low
concentrations, these inhibitors promote
T helper 17 (Th17) cell development by
suppressing Th1 and Th2 cell develop-
ment. Unlike in vitro, CP-690,550 seems
to inhibit JAK1 much less efficiently than
JAK3 in vivo (Yoshida et al., 2012). Thus,
new inhibitors specific to the GQM motif
with a non-ATP-competitive mechanism
could be more specific to JAK1 and
may inhibit STAT3 very efficiently. Such
a drug may be suitable for treatment of
Th17 cell-mediated diseases and cancers
where STAT3 plays critical roles.
Even though Babon et al. (2012)’s
study is extremely elegant, several ques-
tions remain to be solved. First, the inter-
action points between KIR and JH1 were
not clarified in this study because the
KIR region of SOCS3 is unstructured in
the absence of JAK2-JH1. Cocrystal
analysis may be necessary to resolve
this problem. Second, it remains to be
established whether this mechanism ofSOCS3 can be extended to SOCS1. The
SOCS1-IFNGR1 complex may inhibit
JH1 just like the SOCS3-gp130 complex.
However, apparently, the SOCS1 SH2
domain has a high affinity to the activation
loop of JH1 and can inhibit almost all cyto-
kine signaling by overexpression in vivo.
The interaction of SOCS1 with JH1 may
be different from that of SOCS3. The
mechanism of SOCS1 is a challenge of
structural biology because nobody has
been successful in obtaining recombinant
soluble and functional SOCS1 protein.
Third, the current findings should be
translated into drug discovery. In silico
structural modeling of JAKs and SOCS
may facilitate discovery of new drugs
that mimic SOCS.REFERENCES
Alexander, W.S., and Hilton, D.J. (2004). Annu.
Rev. Immunol. 22, 503–529.
Babon, J.J., McManus, E.J., Yao, S., DeSouza,
D.P., Mielke, L.A., Sprigg, N.S., Willson, T.A., Hil-
ton, D.J., Nicola, N.A., Baca, M., et al. (2006).
Mol. Cell 22, 205–216.Immunity 36,Babon, J.J., Sabo, J.K., Zhang, J.G., Nicola, N.A.,
and Norton, R.S. (2009). J. Mol. Biol. 387, 162–174.
Babon, J.J., Kershaw, N.J., Murphy, J.M., Var-
ghese, L.N., Laktyushin, A., Young, S.N., Lucet,
I.S., Norton, R.S., and Nicola, N.A. (2012). Immu-
nity 36, this issue, 239–250.
Doti, N., Scognamiglio, P.L., Madonna, S., Scar-
poni, C., Ruvo, M., Perretta, G., Albanesi, C., and
Marasco, D. (2011). Biochem. J., in press.
Published online December 14, 2011. 10.1042/
BJ20111647.
Sasaki, A., Yasukawa, H., Suzuki, A., Kamizono,
S., Syoda, T., Kinjyo, I., Sasaki, M., Johnston,
J.A., and Yoshimura, A. (1999). Genes Cells 4,
339–351.
Yasukawa, H., Misawa, H., Sakamoto, H., Masu-
hara, M., Sasaki, A., Wakioka, T., Ohtsuka, S., Im-
aizumi, T., Matsuda, T., Ihle, J.N., and Yoshimura,
A. (1999). EMBO J. 18, 1309–1320.
Yasukawa, H., Ohishi, M., Mori, H., Murakami, M.,
Chinen, T., Aki, D., Hanada, T., Takeda, K., Akira,
S., Hoshijima, M., et al. (2003). Nat. Immunol. 4,
551–556.
Yoshida, H., Kimura, A., Fukaya, T., Sekiya, T.,
Morita, R., Shichita, T., Inoue, H., and Yoshimura,
A. (2012). Biochem. Biophys. Res. Commun., in
press. Published online January 9, 2012. 10.
1016/j.bbrc.2011.12.156.
Yoshimura, A., Naka, T., and Kubo, M. (2007). Nat.
Rev. Immunol. 7, 454–465.Toll-like Receptor 9, What O’Clock Is It?Hannah-Lena Obermann1 and Stefan Bauer1,*
1Institute for Immunology, Philipps-University Marburg, BMFZ, Hans-Meerweinstr. 2, 35043 Marburg, Germany
*Correspondence: stefan.bauer@staff.uni-marburg.de
DOI 10.1016/j.immuni.2012.02.003
In this issue of Immunity, Silver et al. (2012) provide evidence that murine Toll-like receptor 9 (TLR9) expres-
sion and function in innate and adaptive immunity is controlled by the circadian cycle.Toll-like receptor 9 (TLR9) belongs to
the TLR family of pattern recognition
receptors (PRRs) that are important for
sensing evading pathogens via con-
served pathogen-associated molecular
patterns (PAMPs). The family of TLRs
consists of 13 members (TLR1 to TLR13)
that sense different PAMPs such as lipo-
polysaccharide, lipoproteins, flagellin,
and nucleic acids (Iwasaki and Medzhi-
tov, 2004). TLR9 is part of a subgroup of
TLRs that is expressed in endosomal
vesicles and recognizes bacterial and
viral DNA with a sequence motif contain-ing the dinucleotide CpG. Importantly,
ligand sensing by TLR9 leads to subse-
quent production of type I interferon,
proinflammatory cytokines and upregula-
tion of costimulatory molecules, signals
essential for initiating and directing an
antigen-driven adaptive immune re-
sponse (Iwasaki and Medzhitov, 2004;
Kumagai et al., 2008). Synthetic CpG-
containing deoxynucleotides that mimic
microbial DNA are undergoing clinical
testing as adjuvant in vaccines and as
immunomodulator against infection or
for the treatment of cancer and allergy(Jurk and Vollmer, 2007). However, under
certain circumstances such as enhanced
DNA uptake, non-CpG-containing DNA
or self-DNA can also activate TLR9 and
induce or sustain certain autoimmune
diseases such as systemic lupus erythe-
matosus (SLE). Accordingly, self-DNA-
antibody complexes trigger TLR9 in SLE
and lead to the production of type I inter-
feron, which is involved in pathogenesis of
the disease. Thus, TLR9 antagonists are
also currently evaluated for therapeutic
use, especially for the treatment of SLE
(Marshak-Rothstein, 2006).February 24, 2012 ª2012 Elsevier Inc. 159
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Figure 1. Influence of Oscillating TLR9 Function on Timing of
Therapeutic Intervention
Gene expression is regulated via the master clock in the hypothalamus, the
suprachiasmatic nucleus (SCN), and peripheral clocks in immune cells by
linked transcriptional and/or translational feedback loops involving so-called
clock genes. Circadian regulation of TLR9 function allows for an optimal timing
of immune intervention such as vaccination and immunotherapy.
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PreviewsMost light-sensitive organ-
isms ranging from cyanobac-
teria to humans have devel-
oped molecular circadian
clocks for anticipating
daytime in order to optimize
their physiology, metabolism,
and behavior (Dibner et al.,
2010). Light and dark cycles
are also thought to influence
immune function of verte-
brate-pathogen interactions.
Circadian rhythms display
near 24 hr oscillations, are
autonomous, and continue
even without external timing
by daylight. A small region in
the hypothalamus, the supra-
chiasmatic nucleus (SCN), is
connected to specific photo-
receptors in the retina and
regulates as master clockthe circadian rhythms via neuronal
connections or endocrine signals.
However, peripheral organs such as liver,
lung, kidney, spleen, heart, and individual
cell lines (e.g., fibroblasts) also possess
circadian oscillators (peripheral clocks),
which are implicated in local physiology
(Dibner et al., 2010). In the immune
system, light and dark cycles are thought
to influence immune functions such as
natural killer cell activity, cytokine levels,
and lymphocyte proliferation (Roberts,
2000). In plants, the circadian clock deter-
mines the efficiency of an immune
response against pathogens (Roden and
Ingle, 2009). A circadian clock in macro-
phages has been identified that controls
inflammatory immune responses upon
stimulation with lipopolysaccharide
(LPS). Transcriptional analysis indicated
that almost 1/10th of all genes expressed
in murine macrophages are transcribed
in a circadian fashion including genes
involved in the LPS-driven signaling
pathway. Accordingly, mRNAs of the
coreceptor CD14 or transcription factors
such as AP-1 oscillate. In contrast, a
circadian control of the LPS receptor
TLR4 itself was not observed (Keller
et al., 2009). At the molecular level, the
oscillations in protein expression are
controlled by linked transcriptional-
translational feedback loops involving
so-called clock genes such as Per1-3
(Period circadian protein homolog),
cryptochromes (Cry1, Cry2), Clock, or
Bmal1 (brain and muscle aryl hydro-160 Immunity 36, February 24, 2012 ª2012 Ecarbon receptor nuclear translocator
[ARNT]-like) (Dibner et al., 2010).
In their study, Silver et al. (2012) show
that Per2 mutant macrophages with a
defective circadian molecular clock due
to a disturbed interaction of Per2 with
other clock proteins produced less
inflammatory cytokines upon TLR9 stimu-
lation when compared to wild-type cells.
Of note, the stimulation of other TLRs
such as TLR2, TLR3, TLR4, and TLR7
resulted in a comparable cytokine re-
sponse in both genotypes, implying a
specific influence of the circadian cycle
on TLR9-driven cytokine production.
TLR9 promoter studies further lead to
the identification of so called E-boxes
that contain target sequences for the
core circadian transcription factor con-
sisting of a BMAL1-CLOCK heterodimer.
Further experiments analyzed TLR9
mRNA expression ex vivo from tissue of
mice that were kept under a 12 hr light/
12 hr dark cycle (Zeitgeber time [ZT] 0 to
24) and sacrificed every 4 hr. Interestingly,
splenic TLR9 mRNA expression peaked
at ZT19 during the active phase of the
animals and showed its nadir at ZT7.
Circadian cycles of TLR9 were also
observed in purified B cells and macro-
phages, though slightly shifted compared
to the whole organ. Surprisingly, dendritic
cells showed no TLR9 oscillation, sug-
gesting a cell type-specific circadian
TLR9 regulation. The circadian rhythm
persisted in spleen and isolated immune
cells from mice kept under constantlsevier Inc.darkness, supporting the
autonomous nature of the
oscillation. Interestingly, pro-
tein expression correlated
with mRNA oscillation, which
implies a short half-life of
TLR9 protein in general or
circadian cycle-dependent
degradation. It will be inter-
esting to investigate in the
future whether Triad3A that
acts as an E3 ubiquitin-protein
ligase and enhances ubiq-
uitination and proteolytic
degradation of TLR9 is regu-
lated by a circadian cycle
(Chuang and Ulevitch, 2004).
Most excitingly, when the
authors investigated the func-
tional consequence of TLR9
stimulation by CpG-DNA in
mice at increased TLR9 ex-pression (ZT19 versusZT7), they observed
substantial elevated amounts of inflamma-
tory cytokines and chemokines as well as
upregulation of costimulatory molecules.
This upregulation was strictly TLR9-
dependent given that cytokine amounts
in unchallenged mice did not oscillate.
These observations strongly suggest that
TLR9-mediated immune activation could
influence adaptive immune responses as
a function of circadian rhythms. Accord-
ingly, immunizations with ovalbumin
antigen and CpG-ODN as adjuvant at
increased TLR9 expression (ZT19) led to
enhanced antigen-specific T cell prolifera-
tion and IFN-g production, underscoring
the fact that circadian oscillations in TLR9
responsiveness have long-term impact
on the adaptive immune response. This
important result implies that intervention
by synthetic TLR9 ligands may also be
tailored in humans for optimized adaptive
immune activation and immunization. If
TLR9 oscillates in humans warrants
further investigation, however, Silver et al.
(2012) have identified three noncanonical
E-boxes in the promoter region that point
to a day time-dependent expression of
human TLR9 via the CLOCK-BMAL1 tran-
scription factor (Figure 1).
In a TLR9-dependent model of polymi-
crobial sepsis utilizing mouse cecal liga-
tion and puncture (CLP), the authors
further observed more severe disease
when CLP was performed at the peak of
splenic TLR9 expression. Wild-type
animals that underwent CLP showed
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Previewsearlier mortality, had higher levels of
inflammatory cytokines in the serum, and
contained increased number of bacteria
in the peritoneum. In humans it has been
noted that septic shock patients have an
increased risk of mortality in the early
morning, suggesting a circadian clock-
dependent response. However, sepsis in
general is not strictly TLR9 dependent
and other TLRs such as TLR2 and TLR4
are important players in gram+ and gram
bacteria-mediated septic shock. There-
fore, apart from TLR9, other PRRs prob-
ably are also under circadian control and
influence immune reactions in a circadian
rhythm-dependent manner.
However, in TLR9-driven autoimmune
diseases such as SLE a possible correla-
tion between oscillating TLR9 expressionand severity of disease could help to opti-
mize the therapeutic efficiencyof immuno-
modulatory reagents such as TLR9 inhibi-
tory ODNs.
Overall, this study has important impli-
cations for TLR9-driven immunotherapy
and will further nourish the research on
the influence of the circadian clock on im-
mune responses and immune
intervention.
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Regulatory T (Treg) cells are thought to be susceptible to conversion into effector T cells. In this issue of
Immunity, Miyao et al. (2012) provide evidence that the apparent plasticity of murine Foxp3+ Treg cells is
largely restricted to a defined subset of poorly committed Foxp3+ cells.Proper functioning of the immune system
implies a tightly balanced regulation of
effector mechanisms to avoid autoimmu-
nity and immunopathology. A variety of
control mechanisms have been identified,
comprising negative feedback circuits
affecting activation, survival, or functioning
of effector cells. Regarding the discrimina-
tion of self from non-self, central tolerance
was initially thought to be the key in avoid-
ing autoimmunity, but the (re)discovery of
specific T cells populations, now called
regulatory T (Treg) cells, that can suppress
self-reactive responses and that are char-
acterized by the expression of the tran-
scription factor Foxp3has led to the insight
that dominant tolerance mediated by
Foxp3+CD4+ Treg cells is a vital compo-
nent of the immunological balance.
Not surprisingly, this population of
Foxp3+ Tcells hasattractedmuch interest,including that of clinical scientists consid-
ering transfer of Treg cells as a valuable
therapy to control life-threatening graft-
versus-host disease, to improve accep-
tance of transplanted organs, or to
suppress autoimmunity in a more specific
way than by currently used therapies.
However, such therapies would encounter
unpredictable risks if the cell type trans-
ferred would be unstable or even could
convert into effector cells producing
inflammatory cytokines, as some recent
experimental data suggested. The ques-
tion of whether Foxp3+ Treg cells repre-
sent a stable lineage or display a substan-
tial degreeof plasticity is therefore amatter
of considerable importance, particularly
because previous investigations resulted
in controversial conclusions.
What is the evidence that Foxp3+ Treg
cells are defined lineages? No doubt thatT cells of a number of functional states
can have suppressive actions. IL-10-
producing CD4+ T cells, for example,
clearly have an important regulatory func-
tion, but so far evidence is rather pointing
to contextual acquisition of this property,
optional both for cells of the Treg cell
lineage as well as for multiple inflamma-
tory phenotypes such as Th1, Th2, or
Th17 cells. IL-10-producing cells lack a
clonal commitment to produce IL-10 and
apparently do not establish an IL-10-
specific cytokine memory; i.e., these cells
do not fulfill the definitions of a stable cell
lineage (Dong et al., 2007).
The situation seemed to be different for
Foxp3+ Treg cells, which is believed to de-
velop autonomously as a separate lineage
within the thymus and to harbor a high
degree of stability both in vitro and in vivo.
However, upon the emergence of moreFebruary 24, 2012 ª2012 Elsevier Inc. 161
